Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that CRLX101 has achieved its primary efficacy endpoint in an ongoing single-arm Phase 2 monotherapy clinical trial in relapsed ovarian cancer.
Researchers at Case Western Reserve University have received a $540,000 federal grant to devise methods for building minute structures tailored to precisely deliver medicines to tumors or carry dyes that help imaging technologies detect disease, create more efficient nanowires and nanoelectonics, and more.
According to a new market report published by Transparency Market Research "Nanomedicine Market (Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology Applications) - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019,"the market for nanomedicine was valued at USD 78.54 billion in 2012 and is expected to reach a value of USD 177.60 billion in 2019, growing at a CAGR of 12.3% from 2013 to 2019.
Researchers at the Winship Cancer Institute of Emory University have discovered a more effective drug delivery system using nanotechnology that could one day significantly affect cancer prevention.
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission (EC) has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.
In 2004, a form of cancer known as neuroblastoma claimed the life of Alexandra (Alex) Scott, a little girl who gained national attention for using her lemonade stand to raise money for cancer research. Now, the organization established in her memory, the Alex's Lemonade Stand Foundation (ALSF), has awarded University of Maryland (UMD) A. James Clark School of Engineering Assistant Professor Christopher M. Jewell a three-year, $375,000 research grant to support the pre-clinical development of a cancer vaccine technology that could give children like Alex a better chance to have a long and healthy life.
Vaccines combat diseases and protect populations from outbreaks, but the life-saving technology leaves room for improvement. Vaccines usually are made en masse in centralized locations far removed from where they will be used. They are expensive to ship and keep refrigerated and they tend to have short shelf lives.
Kala Pharmaceuticals, Inc., a leading developer of innovative ophthalmic products based on the Company’s proprietary Mucus Penetrating Particle (MPP) technology, announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to initiate a Phase 3 clinical program with its MPP-formulated loteprednol etabonate ophthalmic nano-suspension product (LE-MPP) for the treatment of post-operative inflammation and pain following cataract surgery.
Researchers have developed a technique for creating nanoparticles that carry two different cancer-killing drugs into the body and deliver those drugs to separate parts of the cancer cell where they will be most effective. The technique was developed by researchers at North Carolina State University and the University of North Carolina at Chapel Hill.
Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases. The partnership was established to support Astellas' goal of building a global vaccine franchise and launched its first company, RSV Corporation (RSVC), in December 2013.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.